GPER1 and inflammatory breast carcinoma: Interestingly, ERα17p shares not only anti-proliferative and apoptotic activities but also anti-inflammatory and anti-nociceptive actions through GPER, thereby opening new perspectives in the management of inflammatory breast cancer and tumor-mediated pain [52,61].